Beyond Air Reaffirms $8M CY2026 and $16-18M CY2027 Revenue Guidance; FDA Decision on LungFit PH Expected 2H 2026
XAIR is trading near its 52-week low of $5.02 (14% above the low).
Summary
Beyond Air reported flat Q1 revenue of $1.8 million and reaffirmed its CY2026 and CY2027 guidance, while highlighting an FDA decision on its second-generation LungFit PH system expected in 2H 2026.
Key Events · Earnings and Guidance · XAIR
-
Q1 FY2027 Revenue Flat at $1.8M
Revenue for the quarter ended June 30, 2026 was $1.8 million, unchanged from the prior year period. Gross margin improved to 13% from 9%.
-
Reaffirms CY2026 and CY2027 Guidance
Company reaffirmed revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027, representing over 110% year-over-year growth at the midpoint.
-
FDA Decision on LungFit PH Expected 2H 2026
PMA supplement for the second-generation LungFit PH system is under FDA review, with approval expected in the second half of 2026. The system is not included in CY2026 guidance.
-
Commercial Expansion: Third Major GPO Agreement
Entered into a national group purchasing agreement with a leading U.S. GPO, expanding reach by nearly 2,000 U.S. hospitals and health systems.
Analysis · XAIR · Industrial Applications And Services
Beyond Air reported Q1 FY2027 revenue of $1.8 million, flat year-over-year, and reaffirmed its full-year guidance of $8 million for CY2026 and $16-$18 million for CY2027. The company also disclosed that its PMA supplement for the second-generation LungFit PH system is under FDA review with approval expected in the second half of 2026, a key regulatory milestone that could unlock a larger addressable market. The recent $30.1 million financing provides runway, but the company still faces a going concern warning and a net loss of $7.9 million for the quarter.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XAIR was trading at $5.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $5.02 to $95.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.